Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in U.S. older adults.

ABSTRACT:

Background

The 13-valent pneumococcal conjugate vaccine (PCV13) is approved by the U.S. Food and Drug Administration for adults, but its role in older adults is unclear.

Purpose

To compare PCV13 strategies to currently recommended vaccination strategies in adults aged ≥65 years.

Methods

Using a Markov model, the cost effectiveness of PCV13 and the 23-valent pneumococcal polysaccharide vaccine (PPSV23), alone or in combination, was estimated, in adults aged either 65 years or 75 years. No prior vaccination, prior vaccination, and vaccine hyporesponsiveness scenarios were examined. Pneumococcal disease rates, indirect childhood PCV13 effects, and costs were estimated using CDC Active Bacterial Core surveillance data and U.S. national databases. An expert panel estimated

SUBMITTER: Smith KJ 

PROVIDER: S-EPMC3601581 | biostudies-literature | 2013 Apr

REPOSITORIES: biostudies-literature